Generic placeholder image

Current Drug Safety

Editor-in-Chief

ISSN (Print): 1574-8863
ISSN (Online): 2212-3911

Research Article

Impact of Clinical Audit on Adherence to the Guidelines Directed Medical Therapy in Patients Admitted with Heart Failure

Author(s): Aashiq A. Shukkoor, Nimmy E. George*, Shanmugasundaram Radhakrishnan, Sivakumar Velusamy, Tamilarasu kaliappan, Rajendiran Gopalan, Premkrishna Anandan, Ramasamy Palanimuthu and Vidhyakar R. Balasubramanian

Volume 15 , Issue 2 , 2020

Page: [117 - 123] Pages: 7

DOI: 10.2174/1574886315666200310114528

Price: $65

Abstract

Background: The adoption of guideline recommendations of pharmacotherapy to improve the clinical course of Heart Failure (HF) remains below par. Our objective is to evaluate the impact of clinical audit on adherence to the Guideline-Directed Medical Therapy (GDMT) in patients admitted with acute heart failure with reduced ejection fraction (EF).

Methods: A prospective interventional study was conducted over a period of 12 months from June 2018 to May 2019 in all patients admitted with acute heart failure with reduced ejection fraction. The discharge prescriptions of patients who met the inclusion criteria were audited for appropriateness in the usage of neurohormonal blockers and Ivabradine, by a clinical pharmacist on a monthly basis. Audit results were presented to the practicing physicians every month and feedback was given.

Results: Discharge prescriptions of 716 patients who presented with HF were audited for the reasonable or unreasonable omission of neurohormonal blocking drugs. The first-month audit revealed that the unreasonable omission of Angiotensin-Converting Enzyme Inhibitors/ Angiotensin Receptor Blockers/ Angiotensin Receptor Neprilisin Inhibitors ( ACEI/ARB/ARNI), Betablockers and Mineralocorticoid Receptor Antagonists (MRA) were 24.5%, 13.1%, and 9.09% respectively, which reduced to nil at the end of the study period (p=0.00). Initiation of Ivabradine before prescribing or achieving the target dose of Betablocker was noted in 38.18% of patients in the first month, which was also reduced to nil (p=0.00) at the end of the study.

Conclusion: This study reveals that periodic clinical audit improves adherence to GDMT in patients admitted with heart failure with reduced ejection fraction.

Keywords: Heart failure, clinical audit, clinical pharmacist, evidence-based medicine, GDMT, ejection fraction.

Graphical Abstract
[1]
Filippatos G, Khan SS, Ambrosy AP, et al. International registry to assess medical practice with longitudinal observation for Treatment of Heart Failure (REPORT-HF): Rationale for and design of a global registry. Eur J Heart Fail 2015; 17(5): 527-33.
[http://dx.doi.org/10.1002/ejhf.262] [PMID: 25754836]
[2]
Komajda M, Cowie MR, Tavazzi L, Ponikowski P, Anker SD, Filippatos GS. Physicians’ guideline adherence is associated with better prognosis in outpatients with heart failure with reduced ejection fraction: The QUALIFY International Registry. Eur J Heart Fail 2017; 19(11): 1414-23.
[http://dx.doi.org/10.1002/ejhf.887] [PMID: 28463464]
[3]
Harikrishnan S, Sanjay G, Anees T, et al. Clinical presentation, management, in-hospital and 90-day outcomes of heart failure patients in Trivandrum, Kerala, India: The Trivandrum heart failure registry. Eur J Heart Fail 2015; 17(8): 794-800.
[http://dx.doi.org/10.1002/ejhf.283] [PMID: 26011246]
[4]
Reem B, Maya M, Fahad A, Nahid A, Abdulfattah A. The role of the clinical pharmacist in multidisciplinary heart failure clinic at tertiary care hospital. Donn J Med Med Sci 2016; 3(3): 11-4.
[5]
Guha K, Allen CJ, Chawla S, et al. Audit of a tertiary heart failure outpatient service to assess compliance with NICE guidelines. Clin Med (Lond) 2016; 16(5): 407-11.
[http://dx.doi.org/10.7861/clinmedicine.16-5-407] [PMID: 27697799]
[6]
Chang HY, Wang CC, Wei J, et al. Gap between guidelines and clinical practice in heart failure with reduced ejection fraction: Results from TSOC-HFrEF registry. J Chin Med Assoc 2017; 80(12): 750-7.
[http://dx.doi.org/10.1016/j.jcma.2017.04.011] [PMID: 29033112]
[7]
Hollenberg SM, Warner Stevenson L, Ahmad T, et al. 2019 ACC expert consensus decision pathway on risk assessment, management, and clinical trajectory of patients hospitalized with heart failure: A report of the American College of Cardiology Solution Set Oversight Committee. J Am Coll Cardiol 2019; 74(15): 1966-2011.
[http://dx.doi.org/10.1016/j.jacc.2019.08.001] [PMID: 31526538]
[8]
Shanbhag D, Graham ID, Harlos K, et al. Effectiveness of implementation interventions in improving physician adherence to guideline recommendations in heart failure: A systematic review. BMJ Open 2018; 8(3)e017765
[http://dx.doi.org/10.1136/bmjopen-2017-017765] [PMID: 29511005]
[9]
Fonarow GC, Albert NM, Curtis AB, et al. Improving evidence-based care for heart failure in outpatient cardiology practices: Primary results of the registry to improve the use of evidence-based Heart Failure Therapies in the outpatient setting (IMPROVE HF). Circulation 2010; 122(6): 585-96.
[http://dx.doi.org/10.1161/CIRCULATIONAHA.109.934471] [PMID: 20660805]
[10]
Riley JP, Masters J. Practical multidisciplinary approaches to heart failure management for improved patient outcome. Eur Heart J Suppl 2016; 28(18): G43-52.
[http://dx.doi.org/10.1093/eurheartj/suw046]
[11]
Dunn SP, Birtcher KK, Beavers CJ, et al. The role of the clinical pharmacist in the care of patients with cardiovascular disease. J Am Coll Cardiol 2015; 66(19): 2129-39.
[http://dx.doi.org/10.1016/j.jacc.2015.09.025] [PMID: 26541925]
[12]
Grupper A, Zhao YM, Sajgalik P, et al. Effect of neurohormonal blockade drug therapy on outcomes and left ventricular function and structure after left ventricular assist device implantation. Am J Cardiol 2016; 117(11): 1765-70.
[http://dx.doi.org/10.1016/j.amjcard.2016.03.011] [PMID: 27079215]
[13]
von Lueder TG, Kotecha D, Atar D, Hopper I. Neurohormonal blockade in heart failure. Card Fail Rev 2017; 3(1): 19-24.
[http://dx.doi.org/10.15420/cfr.2016:22:2] [PMID: 28785471]
[14]
Hall AS, Winter C, Bogle SM, Mackintosh AF, Murray GD, Ball SG. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. Lancet 1993; 342(8875): 821-8.
[PMID: 8104270]
[15]
Pfeffer MA, Braunwald E, Moyé LA, et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. N Engl J Med 1992; 327(10): 669-77.
[http://dx.doi.org/10.1056/NEJM199209033271001] [PMID: 1386652]
[16]
Ambrosioni E, Borghi C, Magnani B. The effect of the angiotensin-converting-enzyme inhibitor zofenopril on mortality and morbidity after anterior myocardial infarction. Survival of Myocardial Infarction Long-term Evluation (SMILE). N Engl J Med 1995; 332: 80-5.
[http://dx.doi.org/10.1056/NEJM199501123320203] [PMID: 7990904]
[17]
Yusuf S, Pitt B, Davis CE, Hood WB Jr, Cohn JN. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med 1992; 327(10): 685-91.
[http://dx.doi.org/10.1056/NEJM199209033271003] [PMID: 1463530]
[18]
Konstam MA, Kronenberg MW, Rousseau MF, et al. Effects of the angiotensin converting enzyme inhibitor enalapril on the long-term progression of left ventricular dilatation in patients with asymptomatic systolic dysfunction. Circulation 1993; 88(5 Pt 1): 2277-83.
[http://dx.doi.org/10.1161/01.CIR.88.5.2277] [PMID: 8222122]
[19]
Davie AP, McMurray JJ. ACE inhibitors and heart failure in hospital: Any difference between cardiologists and general physicians? Postgrad Med J 1999; 75(882): 219-22.
[http://dx.doi.org/10.1136/pgmj.75.882.219] [PMID: 10715761]
[20]
Chatterjee S, Biondi-Zoccai G, Abbate A, et al. Benefits of beta blockers in patients with heart failure and reduced ejection fraction: network meta- analysis. BMJ 2013; 16: 346-55.
[http://dx.doi.org/10.1136/bmj.f55] [PMID: 23325883]
[21]
Lee HY, Baek SH. Optimal use of beta blockers for congestive heart failure. Circ J 2016; 80(3): 565-71.
[http://dx.doi.org/10.1253/circj.CJ-16-0101] [PMID: 26902451]
[22]
Butler J, Ezekowitz JA, Collins SP, et al. Update on aldosterone antagonists use in heart failure with reduced left ventricular ejection fraction. Heart Failure Society Of American Guidelines Committee. J Card Fail 2012; 18(4): 265-81.
[http://dx.doi.org/10.1016/j.cardfail.2012.02.005] [PMID: 22464767]
[23]
Zannad F, Gattis Stough W, Rossignol P, et al. Mineralocorticoid receptor antagonists for heart failure with reduced ejection fraction: Integrating evidence into clinical practice. Eur Heart J 2012; 33(22): 2782-95.
[http://dx.doi.org/10.1093/eurheartj/ehs257] [PMID: 22942339]
[24]
Yancy CW, Jessup M, Bozkurt B, et al. 2016 ACC/AHA/HFSA focused update on new pharmacological therapy for heart failure: An update of the 2013 ACCF/AHA guideline for the management of heart failure: A report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. Circulation 2016; 134(13): e282-93.
[http://dx.doi.org/10.1161/CIR.0000000000000435] [PMID: 27208050]

Rights & Permissions Print Export Cite as
© 2022 Bentham Science Publishers | Privacy Policy